Table 3.

Deterministic base-case analysis for semaglutide versus dulaglutide as an add-on to metformin

	Deterministic base-case
	Semaglutide 0.5 mg	Dulaglutide 0.75 mg	Difference	Semaglutide 1.0 mg	Dulaglutide 1.5 mg	Difference
Health gain
Survival after 40 years, %	4.6	4.6	0	4.7	4.6	0.1
Life-years	17.79	17.77	0.02	17.81	17.77	0.05
QALYs	11.10	11.07	0.04	11.12	11.07	0.05
Direct costs, CAN$
Antihyperglycemic treatment	25,501	25,481	20	25,534	25,476	58
Hypoglycemia	181	231	− 50	212	236	− 24
Macrovascular complications
IHD	13,755	13,628	127	13,717	13,765	− 48
CHF	7664	7692	− 27	7687	7719	− 33
MI	8655	8627	28	8573	8674	− 101
Stroke	5482	5510	− 29	5356	5518	− 161
Microvascular complications
Retinopathy	1306	1354	− 48	1288	1319	− 31
Neuropathy	20,564	20,703	− 139	20,510	20,579	− 69
Nephropathy	2983	3075	− 93	2935	3007	− 72
Total	86,090	86,302	− 212	85,812	86,292	− 480
Production loss costs, CAN$	27,197	27,388	− 191	27,172	27,403	− 231
Total costs, CAN$	113,287	113,690	− 403	112,983	113,695	− 711
Incremental cost-effectiveness ratio
Per life-year gained			Dominant			Dominant
Per QALY gained			Dominant			Dominant

CAN$ Canadian dollars, CHF congestive heart failure, IHD ischemic heart disease, MI myocardial infarction, QALY quality-adjusted life-year